Ask AI
ProCE Banner Activity

BRUIN CLL-322: Phase III Trial of Fixed-Duration Pirtobrutinib + Venetoclax/Rituximab vs Venetoclax/Rituximab in Previously Treated CLL/SLL

Conference Coverage
Slideset

In the randomized phase III BRUIN CLL-322 trial, fixed-duration pirtobrutinib plus venetoclax/rituximab demonstrated a significant PFS benefit vs venetoclax/rituximab in patients with R/R CLL, including those previously treated with cBTKi.

Released: June 25, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with hematologic malignancies. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from studies of hematologic malignancies at ASCO 2026 and EHA 2026 along with expert guidance to optimize personalized care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify patients with hematologic malignancies most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for hematologic malignancies to accelerate their effective incorporation into clinical practice

  • Support informed shared decision-making for patients with hematologic malignancies through accessible discussion of the potential clinical implications of recently presented data at ASCO 2026 and EHA 2026